/
/
ASH 2018: Ninlaro as a Maintenance Therapy After Transplant
ASH 2018: Ninlaro as a Maintenance Therapy After Transplant image
ASH 2018: Ninlaro as a Maintenance Therapy After Transplant
Posted Dec 04, 2018

Dr. Meletios A Dimopoulos presented an abstract which compared the use of Ixaomib to a placebo for maintenance after a stem cell transplant.  This clinical trial was called Tourmaline-MM3, and was chosen as a top 5 abstract by 2 of the 4 doctors who had provided their "Best of the Best" abstracts.

 
This is the first randomized trial which effectively shows a 39% improvement in progression free survival of an proteasome inhibitor over no maintenance.  This now becomes another possible available maintenance strategy.  When compared to a previous trial of lenalidomide vs. placebo after stem cell transplant the improvement with lenalidomide was over 100%, however the survival rate after a median follow up of 86 months was only 18%.  The Ixazomib trial has not a median follow up of just about two years and no data on the difference in Overall Survival was reported.  This should happen in the future, and will be the true measure of Ixazomib as a single agent for maintenance.
 
Dr. Dimopoulos noted he felt the comparison is somewhat moot because the future of treatments is trending towards combinations and maintenance with ixazomib would be used in this context.

For more information, watch the video of Dr. Francesca Gay describing the results of this study. 
 
 
 
 
The author Jennifer Ahlstrom

about the author
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of Myeloma Crowd by HealthTree and the HealthTree Foundation.

More Myeloma News Articles

Get the latest thought leadership on Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Myeloma Newsletter" for Myeloma news, life with Myeloma stories, Myeloma clinical trials, Myeloma 101 articles and events with Myeloma experts.

Thanks to our HealthTree Community for Myeloma Sponsors:

Genentech
Abbvie
Bristol Myers Squibb
Janssen Oncology
GSK

Follow Us

facebook instagram twitter youtube

Copyright © 2022 HealthTree Foundation. All Rights Reserved.

The HealthTree Foundation / Myeloma Crowd is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811

 https://www.guidestar.org/profile/45-5354811